1. Home
  2. PBYI vs CVEO Comparison

PBYI vs CVEO Comparison

Compare PBYI & CVEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PBYI
  • CVEO
  • Stock Information
  • Founded
  • PBYI 2010
  • CVEO 1977
  • Country
  • PBYI United States
  • CVEO United States
  • Employees
  • PBYI N/A
  • CVEO N/A
  • Industry
  • PBYI Biotechnology: Pharmaceutical Preparations
  • CVEO Hotels/Resorts
  • Sector
  • PBYI Health Care
  • CVEO Consumer Discretionary
  • Exchange
  • PBYI Nasdaq
  • CVEO Nasdaq
  • Market Cap
  • PBYI 263.4M
  • CVEO 284.2M
  • IPO Year
  • PBYI N/A
  • CVEO N/A
  • Fundamental
  • Price
  • PBYI $4.91
  • CVEO $21.69
  • Analyst Decision
  • PBYI Strong Buy
  • CVEO Strong Buy
  • Analyst Count
  • PBYI 1
  • CVEO 1
  • Target Price
  • PBYI $7.00
  • CVEO $27.00
  • AVG Volume (30 Days)
  • PBYI 635.5K
  • CVEO 74.9K
  • Earning Date
  • PBYI 11-06-2025
  • CVEO 10-31-2025
  • Dividend Yield
  • PBYI N/A
  • CVEO 2.31%
  • EPS Growth
  • PBYI 59.87
  • CVEO N/A
  • EPS
  • PBYI 0.74
  • CVEO N/A
  • Revenue
  • PBYI $211,995,000.00
  • CVEO $628,180,000.00
  • Revenue This Year
  • PBYI N/A
  • CVEO N/A
  • Revenue Next Year
  • PBYI N/A
  • CVEO $2.62
  • P/E Ratio
  • PBYI $6.61
  • CVEO N/A
  • Revenue Growth
  • PBYI N/A
  • CVEO N/A
  • 52 Week Low
  • PBYI $2.32
  • CVEO $18.01
  • 52 Week High
  • PBYI $6.12
  • CVEO $27.55
  • Technical
  • Relative Strength Index (RSI)
  • PBYI 46.97
  • CVEO 43.52
  • Support Level
  • PBYI $4.58
  • CVEO $21.62
  • Resistance Level
  • PBYI $6.12
  • CVEO $22.66
  • Average True Range (ATR)
  • PBYI 0.40
  • CVEO 0.82
  • MACD
  • PBYI -0.05
  • CVEO -0.06
  • Stochastic Oscillator
  • PBYI 20.06
  • CVEO 35.09

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

About CVEO Civeo Corporation (Canada)

Civeo Corp provides hospitality services to the natural resources industry in Canada, Australia and the United States. The company provides a full suite of services for guests, including lodging, catering and food service, housekeeping and maintenance at accommodation facilities that the company or its customers own. The company provides services that support the day-to-day operations of these facilities, such as laundry, facility management and maintenance, water and wastewater treatments, power generation, communication systems, security and logistics. The company operates in active oil, metallurgical coal, liquefied natural gas and iron ore-producing regions. The company operates in three reportable business segments Canada, Australia and the United States.

Share on Social Networks: